[Long term eradication rate of mebendazole therapy for strongyloidiasis]
- PMID: 1624824
- DOI: 10.11150/kansenshogakuzasshi1970.66.354
[Long term eradication rate of mebendazole therapy for strongyloidiasis]
Abstract
We treated 245 strongyloidiasis patients with 7 schedules of mebendazole (MBZ) and obtained the eradication rates at 8 months to 2 years after the final treatment as described follows; MBZ (100 mg) was given twice a day orally. [Square bracket shows incidence of liver disfunction.] 1) The eradication rates at 2 years after single course of MBZ therapy for 28 days and a combination therapy (thiabendazole 500 mg powder form three times daily for 5 days followed by MBZ in powder form for 9 days, repeated once) were 93.8% (15 of 16 patients), [71.4%] and 100.0% (16/16), [50.0%]. 2) The eradication rates at 8-15 months after using MBZ alone in varying dosages were as follows: a) MBZ powder was administered for 5 days and was then repeated 1, 3 and 4 weeks later: 87.1 (27/31), [51.1%]. b) MBZ powder was given for 5 days and repeated 1 and 3 weeks later: 100.0% (7/7), [30.8%]. c) MBZ powder was administered for 4 days and repeated 1, 3 and 4 weeks later: 96.3% (26/27), [57.8%]. d) MBZ in tablet form was given for 4 days and repeated 1, 3 and 4 weeks later: 89.6% (43/48). [66.2%]. e) MBZ in tablet form was administered for 4 days and repeated 1 week later: 69.2% (9/13), [25.0%]. As described above, although the incidence of liver disfunction in the 4-day with 2-course therapy was lower than the other schedules, the eradication rate was lower. From these results, MBZ should be given to strongylodiasis patient for 4 days and repeated once, or for 3 days and repeated two or three times with 1 to 2 weeks intervals.
Similar articles
-
[Treatment of strongyloidiasis with mebendazole--long-term eradication and new trials].Kansenshogaku Zasshi. 1991 Apr;65(4):433-41. doi: 10.11150/kansenshogakuzasshi1970.65.433. Kansenshogaku Zasshi. 1991. PMID: 2071960 Clinical Trial. Japanese.
-
[Comparison of efficacy of powder and tablet of mebendazole in the treatment of strongyloidiasis].Kansenshogaku Zasshi. 1991 Jun;65(6):681-6. doi: 10.11150/kansenshogakuzasshi1970.65.681. Kansenshogaku Zasshi. 1991. PMID: 1919097 Clinical Trial. Japanese.
-
[Treatment of strongyloidiasis with mebendazole and its combination with thiabendazole].Kansenshogaku Zasshi. 1990 Nov;64(11):1408-15. doi: 10.11150/kansenshogakuzasshi1970.64.1408. Kansenshogaku Zasshi. 1990. PMID: 2286784 Japanese.
-
[Strongyloidosis. Part IX. Treatment].Wiad Parazytol. 2002;48(2):173-96. Wiad Parazytol. 2002. PMID: 16888940 Review. Polish.
-
Strongyloidiasis--progress in diagnosis and treatment.Intern Med. 2000 Sep;39(9):695-700. doi: 10.2169/internalmedicine.39.695. Intern Med. 2000. PMID: 10969899 Review.
Cited by
-
Strongyloidiasis: a conundrum for gastroenterologists.Gut. 1994 Apr;35(4):437-40. doi: 10.1136/gut.35.4.437. Gut. 1994. PMID: 8174976 Free PMC article. Review. No abstract available.
-
Strongyloides ratti: in vitro and in vivo activity of tribendimidine.PLoS Negl Trop Dis. 2008 Jan 23;2(1):e136. doi: 10.1371/journal.pntd.0000136. PLoS Negl Trop Dis. 2008. PMID: 18235851 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials